Background: Multiple sclerosis (MS) is one of the most common chronic immune-mediated diseases of the human central nervous system and an important cause of non-traumatic neurologic disability among young population in several countries. Recent reports from East Asia, South East Asia and South Asia have proposed a low to moderate prevalence of MS in these countries. Methods: A literature review search was carried out in December 2014 in Medline, Embase, Scopus and Cochrane library to recover original population-based studies on MS epidemiology in East Asia, South East Asia and South Asia countries published between January 1, 1950 and December 30, 2014. We intended search strategies using the key words: multiple sclerosis, prevalence, incidence and epidemiology. Based on our inclusion criteria, 68 epidemiologic studies were included in this systematic review. Results: The most extensively used diagnostic criteria in the studies were McDonald's criteria. Most studies were performed in a multi-center hospital setting. The female to male ratio varied and ranged from 0.7 in India to 9.0 in China. The mean age at disease onset ranged from the lowest age of 25.3 in Iran to the highest age of 46.4 in China. MS prevalence ranged from 0.77 in 100,000 populations in Hong Kong (1999) to 85.80 in 100,000 in Iran (2013). Conclusions: Advances in MS registries around the globe allow nationwide population-based studies and will allow worldly comparisons between the prevalence and incidence in different regions that are provided to monitor estimation.

Keywords:
Multiple sclerosis, Epidemiology, Prevalence, East Asia, South East Asia, South Asia
1.
Marrie R, Horwitz RI: Emerging effects of comorbidities on multiple sclerosis. Lancet Neurol 2010;9:820-828.
2.
Benamer H, Ahmed ES, Al-Din AS, Grosset DG: Frequency and clinical patterns of multiple sclerosis in Arab countries: a systematic review. J Neurol Sci 2009;278:1-4.
3.
Cristiano E, Patrucco L, Rojas JI: A systematic review of the epidemiology of multiple sclerosis in South America. Eur J Neurol 2008;15:1273-1278.
4.
Bowne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor BV, Thompson AJ, et al: Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology 2014;83:1022-1024.
5.
Kurtzke JF: Epidemiologic contributions to multiple sclerosis: an overview. Neurology 1980;30(7 pt 2):61-79.
6.
Evans C, Beland SG, Kulaga S, Wolfson C, Kingwell E, Marriott J, et al: Incidence and prevalence of multiple sclerosis in the Americas: a systematic review. Neuroepidemiology 2013;40:195-210.
7.
Melcon MO, Correale J, Melcon CM: Is it time for a new global classification of multiple sclerosis? J Neurol Sci 2014;344:171-181.
8.
Kira J: Multiple sclerosis in the Japanese population. Lancet Neurol 2003;2:117-127.
9.
Wasay M, Khatri IA, Khealani B, Sheerani M: MS in Asian countries. Int MS J 2006;13:58-65.
10.
Schumacher GA, Beebe G, Kibler RF, Kurland LT, Kurtzke JF, McDowell F, Nagler B, Sibley WA, Tourtellotte WW, Willmon TL: Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann N Y Acad Sci 1965;122:552-568.
11.
Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al: New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
12.
McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al: Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127.
13.
Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al: Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘McDonald criteria'. Ann Neurol 2005;58:840-846.
14.
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al: Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.
16.
Munn Z, Moola S, Riitano D, Lisy K: The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence. Int J Health Policy Manag 2014;3:123-128.
17.
Houzen H, Niino M, Hirotani M, Fukazawa T, Kikuchi S, Tanaka K, et al: Increased prevalence, incidence, and female predominance of multiple sclerosis in northern Japan. J Neurol Sci 2012;323:117-122.
18.
Houzen H, Niino M, Hata D, Nakano F, Kikuchi S, Fukazawa T, et al: Increasing prevalence and incidence of multiple sclerosis in northern Japan. Mult Scler 2008;14:887-892.
19.
Osoegawa M, Kira J, Fukazawa T, Fujihara K, Kikuchi S, Matsui M, et al: Temporal changes and geographical differences in multiple sclerosis phenotypes in Japanese: nationwide survey results over 30 years. Mult Scler 2009;15:159-173.
20.
Tanaka K, Kujuro Y, Suzuki S, Tanahashi N, Hamada J, Nogawa S, et al: Clinical and laboratory features of in-patients with multiple sclerosis in a University Hospital in Tokyo from 1988-2002. Intern Med 2005;44:560-566.
21.
Itoh T, Aizawa H, Hashimoto K, Yoshida K, Kimura T, Katayama T, Koyama S, et al: Prevalence of multiple sclerosis in Asahikawa, a city in northern Japan. J Neurol Sci 2003;214:7-9.
22.
Houzen H, Niino M, Kikuchi S, Fukazawa T, Nogoshi S, Matsumoto H, et al: The prevalence and clinical characteristics of MS in northern Japan. J Neurol Sci 2003;211:49-53.
23.
Kira J, Yamasaki K, Horiuchi I, Ohyagi Y, Taniwaki T, Kawano Y: Changes in the clinical phenotypes of multiple sclerosis during the past 50 years in Japan. J Neurol Sci 1999;166:53-57.
24.
Fukazawa T, Tashiro K, Hamada T, Moriwaka F, Matsumoto A, Shima K, et al: Multiple sclerosis in Hokkaido, the Northernmost Island of Japan: prospective analyses of clinical feature. Intern Med 1992;31:349-352.
25.
Kuroiwa Y, Shibasaki H, Ikeda M: Prevalence of multiple sclerosis and its north-to-south gradient in Japan. Neuroepidemiology 1983;2:62-69.
26.
Kuroiwa Y, Igata A, Itahara K, Koshijima S, Tsubaki T: Nationwide survey of multiple sclerosis in Japan. Clinical analysis of 1,084 cases. Neurology 1975;25:845-851.
27.
Shibasaki H, Kuroda Y, Kuroiwa Y: Clinical studies of multiple sclerosis in Japan: classical multiple sclerosis and Devic's disease. J Neurol Sci 1974;23:215-222.
28.
Okinaka S, Tsubaki T, Kuroiwa Y, Toyokura Y, Imamura Y: Multiple sclerosis and allied diseases in Japan; clinical characteristics. Neurology 1958;8:756-763.
29.
Okinaka S, Kurowia Y: Multiple sclerosis and allied diseases in Japan: epidemiological and clinical aspects. Prog Brain Res 1966;21:183-191.
30.
Li T, Xiao H, Li S, Du X, Zhou J: Multiple sclerosis: clinical features and MRI findings in northern China. Eur J Med Res 2014;19:20.
31.
Liu Y, Duan Y, Yu C, Qin W, Chen H, Dong H, et al: Clinical isolated syndrome: a 3-year follow-up study in China. Clin Neurol Neurosurg 2011;113:658-660.
32.
Cheng X, Cheng Q, Xu LZ, Zhao HQ, Zhao Z, Wang W, et al: Evaluation of multiple sclerosis diagnostic criteria in Suzhou, China - risk of under-diagnosis in a low prevalence area. Acta Neurol Scand 2010;121:24-29.
33.
Cheng Q, Miao L, Zhang J, Ding SJ, Liu ZG, Wang X, et al: A population-based survey of multiple sclerosis in Shanghai, China. Neurology 2007;68:1495-1500.
34.
Cheng Q, Miao L, Zhang J, Guan YT, Liu ZG, Wang X, et al: Clinical features of patients with multiple sclerosis from a survey in Shanghai, China. Mult Scler 2008;14:671-678.
35.
Zhao B, Liu XQ, Guo YP, Yang YC, Huang HF: Multiple sclerosis. A clinical study of 70 cases. Eur Neurol 1981;20:394-400.
36.
Kim S, Huh SY, Kim W, Park MS, Ahn SW, Cho JY, et al: Clinical characteristics and outcome of multiple sclerosis in Korea: does multiple sclerosis in Korea really differ from that in the Caucasian populations? Mult Scler 2013;19:1493-1498.
37.
Kim NH, Kim HJ, Cheong HK, Kim BJ, Lee KH, Kim EH, et al: Prevalence of multiple sclerosis in Korea. Neurology 2010;75:1432-1438.
38.
Lee SS, Sohn EH, Nam SW: Preliminary studies on the clinical features of multiple sclerosis in Korea. J Clin Neurol 2006;2:231-237.
39.
Cho Y, Jeon B, Kim Y, Chang K: Clinical features and outcomes from diagnostic work-up in definite multiple sclerosis. J Korean Neurol Assoc 1999;17:823-828.
40.
Kurtzke J, Park C, Oh S: Multiple sclerosis in Korea. Clinical features and prevalence. J Neurol Sci 1968;6:463-481.
41.
Chan KH, Tsang KL, Ho PW, Tse CT, Kwan JS, Ho JW, et al: Clinical outcome of relapsing remitting multiple sclerosis among Hong Kong Chinese. Clin Neurol Neurosurg 2011;113:617-622.
42.
Lau K, Wong W, Sheng B, Yu I, Fung B, Li H, et al: The clinical course of multiple sclerosis patients in Hong Kong. J Neurol Sci 2008;268:78-82.
43.
Lau KK, Wong LK, Li LS, Chan YW, Li HL, Wong V: Epidemiological study of multiple sclerosis in Hong Kong Chinese: questionnaire survey. Hong Kong Med J 2002;8:77-80.
44.
Yu Y, Woo E, Hawkins BR, Ho HC, Huang CY: Multiple sclerosis amongst Chinese in Hong Kong. Brain 1989;112(pt 6):1445-1467.
45.
Lai CH, Tseng HF: Population-based epidemiological study of neurological diseases in Taiwan: I. Creutzfeldt-Jakob disease and multiple sclerosis. Neuroepidemiology 2009;33:274-253.
46.
Chang KH, Lyu RK, Chen CM, Hsu WC, Wu YR, Chen ST, et al: Clinical characteristics of multiple sclerosis in Taiwan: a cross-sectional study. Mult Scler 2006;12:501-506.
47.
Tsai CP, Yuan CL, Yu HY, Chen C, Guo YC, Shan DE: Multiple sclerosis in Taiwan. J Chin Med Assoc 2004;67:500-505.
48.
Hung TP, Landsborough D, Hsi MS: Multiple sclerosis amongst Chinese in Taiwan. J Neurol Sci 1976;27:459-484.
49.
Viswanathan S, Rose N, Masita A, Dhaliwal JS, Puvanarajah SD, Rafia MH, et al: Multiple sclerosis in Malaysia: demographics, clinical features, and neuroimaging characteristics. Mult Scler Int 2013;2013:614716.
50.
Tan CT: Multiple sclerosis in Malaysia. Neurol J Southeast Asia 1997;2:1-5.
51.
Tan CT: Multiple sclerosis in Malaysia. Arch Neurol 1988;45:624-627.
52.
Siritho S, Prayoonwiwat N: A retrospective study of multiple sclerosis in Siriraj Hospital, Bankok, Thailand. Can J Neurol Sci 2007;34:99-104.
53.
Vejjajiva A: Multiple sclerosis in Thailand. Neurol J Southeast Asia 1977;2:7-10.
54.
Jitpimolmard S, Vejjajiva A: Clinical features and clinical course of multiple sclerosis in Thai patients: a report of 50 cases. J Med Assoc Thai 1994;77:239-243.
55.
Pandit L, Kundapur R: Prevalence and patterns of demyelinating central nervous system disorders in urban Mangalore, South India. Mult Scler 2014;20:1651-1653.
56.
Sarma GRK, Nagaraj D: Multiple sclerosis in South India. Ann Indian Acad Neurol 2005;8:71-74.
57.
Syal P, Prabhakar S, Thussu A, Sehgal S, Khandelwal N: Clinical profile of multiple sclerosis in north-west India. Neurol India 1999;47:12-17.
58.
Wadia NH, Bhatia K: Multiple sclerosis is prevalent in the Zoroastrians (Parsis) of India. Ann Neurol 1990;28:177-179.
59.
Singhal BS: Multiple sclerosis. Neurol India 1999;47:1-2.
60.
Chopra JS, Radhakrishnan K, Sawhney BB, Pala N, Banerjee A: Multiple sclerosis in North-West India. Acta Neurol Scand 1980;62:312-321.
61.
Singhal BS, Wadia NH: Profile of multiple sclerosis in the Bombay region. On the basis of critical clinical appraisal. J Neurol Sci 1975;26:259-270.
62.
Mathew NT, Mathai KV, Abraham J, Taori GM: Incidence and pattern of demyelinating disease in India. J Neurol Sci 1971;13:27-38.
63.
Wasay M, Ali S, Khatri IA, Hassan A, Asif M, Zakiullah N, et al: Multiple sclerosis in Pakistan. Mult Scler 2007;13:668-669.
64.
Wasay M, Rizvi F, Azeemuddin M, Yousuf A, Fredrikson S: Incidental MRI lesions suggestive of multiple sclerosis in asymptomatic patients in Karachi, Pakistan. J Neurol Neurosurg Psychiatry 2011;82:83-85.
65.
Etemadifar M, Izadi S, Nikseresht A, Sharifian M, Sahraian MA, Nasr Z: Estimated prevalence and incidence of multiple sclerosis in Iran. Eur Neurol 2014;72:370-374.
66.
Etemadifar M, Abtahi SH, Akbari M, Murray RT, Ramagopalan SV, Fereidan-Esfahani M: Multiple sclerosis in Isfahan, Iran: an update. Mult Scler 2013;20:1145-1147.
67.
Saman-Nezhad B, Rezaee T, Bostani A, Najafi F, Aghaei A: Epidemiological characteristics of patients with multiple sclerosis in Kermanshah, Iran in 2012. J Mazandaran Univ Med Sci 2013;23:97-101.
68.
Rezaali S, Khalilnezhad A, Naser Moghadasi A, Chaibakhsh S, Sahraian MA: Epidemiology of multiple sclerosis in Qom: demographic study in Iran. Iran J Neurol 2013;12:136-143.
69.
Izadi S, Nikseresht A, Sharifian M, Sahraian MA, Hamidian Jahromi A, Aghighi M, et al: Significant increase in the prevalence of multiple sclerosis in Iran in 2011. Iran J Med Sci 2014;39:152-153.
70.
Jajvandian R, Ali Babai A, Torabzadeh S, Rakhshi N, Nikravesh A: Prevalence of multiple sclerosis in North Khorasan province, northern Iran. 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis. Amsterdam, 2011, pp S84-S85.
71.
Majdinasab N. Nakhostin-Mortazavi A, Alemzadeh-Ansari MH: Epidemiologic features of multiple sclerosis in south-western Iran. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, Multiple Sclerosis, 2012, p 311.
72.
Heydarpour P, Mohammad K, Yekaninejad MS, Elhami SR, Khoshkish S, Sahraian MA: Multiple sclerosis in Tehran, Iran: a joinpoint trend analysis. Mult Scler 2014;20:512.
73.
Etemadifar M, Maghzi AH: Sharp increase in the incidence and prevalence of multiple sclerosis in Isfahan, Iran. Mult Scler 2011;17:1022-1027.
74.
Moghaddam AH. Iranmanesh F, Vakilian A: Epidemiology of multiple sclerosis in Rafsanjan: south of Iran. Mult Scler J 2013;650.
75.
Ghandehari K, Riasi HR, Nourian A, Boroumand AR: Prevalence of multiple sclerosis in north east of Iran. Mult Scler 2010;16:1525-1526.
76.
Hashemilar M, Savadi Ouskui D, Farhoudi M, Ayromlou H, Asadollahi A: Multiple sclerosis in east Azerbaijan, north west Iran. Neurol Asia 2011;16:127-131.
77.
Sharafaddinzadeh N, Moghtaderi A, Majdinasab N, Dahmardeh M, Kashipazha D, Shalbafan B: The influence of ethnicity on the characteristics of multiple sclerosis: a local population study between Persians and Arabs. Clin Neurol Neurosurg 2013;115:1271-1275.
78.
Elhami SR, Mohammad K, Sahraian MA, Eftekhar H: A 20-year incidence trend (1989-2008) and point prevalence (March 20, 2009) of multiple sclerosis in Tehran, Iran: a population-based study. Neuroepidemiology 2011;36:141-147.
79.
Sahraian MA, Khorramnia S, Ebrahim MM, Moinfar Z, Lotfi J, Pakdaman H: Multiple sclerosis in Iran: a demographic study of 8,000 patients and changes over time. Eur Neurol 2010;64:331-336.
80.
Abedini M, Habibi-Saravi R, Zarvani A, Farahmand M: Epidemiology of multiple sclerosis in Mazandran province in 2007 (in Persian). J Mazandaran Univ Med Sci 2008;18:82-87.
81.
Saadatnia M, Etemadifar M, Maghzi AH: Multiple sclerosis in Isfahan, Iran. Int Rev Neurobiol 2007;79:357-375.
82.
Etemadifar M, Janghorbani M, Shaygannejad V, Ashtari F: Prevalence of multiple sclerosis in Isfahan, Iran. Neuroepidemiology 2006;27:39-44.
83.
Kalanie H, Gharagozli K, Kalanie AR: Multiple sclerosis: report on 200 cases from Iran. Mult Scler 2003;9:36-38.
84.
Ebrahimi HA Sedighi B: Prevalence of multiple sclerosis and environmental factors in Kerman province, Iran. Neurology Asia 2013;18:385-389.
85.
Shibasaki H, Kubo N, Nishitani H, Saida T, Ohno Y, Fukuyama Y: Nationwide survey of multiple sclerosis in Japan: reappraisal of clinical features. J Trop Geo Neurol 1992;2:73-82.
86.
Rosati G: The prevalence of multiple sclerosis in the world: an update. Neurol Sci 2001;22:117-139.
87.
Etemadifar M, Sajjadi S, Nasr Z, Firoozeei TS, Abtahi SH, Akbari M, et al: Epidemiology of multiple sclerosis in Iran: a systematic review. Eur Neurol 2013;70:356-363.
88.
Kurtzke J: MS epidemiology world wide. One view of current status. Acta Neurol Scand Suppl 1995;161:23-33.
89.
Koch-Henriksen N, Sørensen PS: The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010;9:520-532.
90.
Alshubaili AF, Alramzy K, Ayyad YM, Gerish Y: Epidemiology of multiple sclerosis in Kuwait: new trends in incidence and prevalence. Eur Neurol 2005;53:125-131.
91.
El-Salem K, Al-Shimmery E, Horany K, Al-Refai A, Al-Hayk K, Khader Y: Multiple sclerosis in Jordan: a clinical and epidemiological study. J Neurol 2006;253:1210-1216.
92.
Heydarpour P, Khoshkish S, Abtahi S, Moradi-Lakeh M, Sahraian MA: Multiple sclerosis epidemiology in middle east and north Africa: a systematic review and meta-analysis. Neuroepidemiology 2015;44:232-244.
93.
Ladogana A, Puopolo M, Croes EA, Budka H, Jarius C, Collins S, et al: Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada. Neurology 2005;64:1586-1591.
94.
Noonan CW, Williamson DM, Henry JP, Indian R, Lynch SG, Neuberger JS, et al: The prevalence of multiple sclerosis in 3 US communities. Prev Chronic Dis 2010;7:A12.
95.
Niedziela N, Adamczyk-Sowa M, Pierzchala K: Epidemiology and clinical record of multiple sclerosis in selected countries: a systematic review. Int J Neurosci 2014;124:322-330.
96.
Hader WJ, Yee IM: Incidence and prevalence of multiple sclerosis in Saskatoon, Saskatchewan. Neurology 2007;69:1224-1229.
97.
Koch-Henriksen N, Sørensen PS: The changing demographic pattern of multiple sclerosis epidemiology Lancet Neurol 2010;9:520-532.
98.
Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264-269.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.